Giorgia Guglielmi
Giorgia Guglielmi is a freelance science writer based in Basel, Switzerland. Specializing in life sciences, medicine, and the relationship between science and society, she has published numerous articles in outlets including Nature, Science, and Scientific American. She holds a PhD in biology from the European Molecular Biology Laboratory and a Master’s in Science Writing from the Massachusetts Institute of Technology. She has received recognition for her work, including the John Kendrew Award in 2020 and an ERC-funded FRONTIERS Media Fellowship in 2025. She has also led lectures and workshops on science communication at institutions such as Harvard University and the University of Zurich.
The evolutionary history of the human microbiota could help to understand the role of present-day gut microbes in health and disease.
Targeted manipulation to promote the microbial diversity could be an important strategy to treat long COVID-19 and speed up recovery.
Several bacteria associated with human health are acquired late in childhood — albeit with different developmental dynamics.
Gut bacteria from people in industrialized countries exchange genes at much higher rates than bacteria from people living in non-industrialized societies.
The microbial communities inhabiting the gut have been shown to change in ways that influence the development of disease through blood metabolites.
A molecule in breast milk, called betaine, may lower the risk of obesity by preventing accelerated growth in newborns and supporting bacterial species.
A targeted decontamination could be a strategy to control the spreading of carbapenem-resistance plasmids both amoung patients and within patients.
S. mutans produces tryglysin to inhibit the growth of competing species, including other streptococci that could cause opportunistic infection.
The manipulation of microbiota could improve the outcomes of infections in the respiratory tract cause by opportunistic pathogens.
Gut microbes contribute to symptoms associated with neurological conditions. New microbe-inspired therapies could be develop to treat such conditions.
